Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19018817 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018805 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018773 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018754 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018788 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18434159 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | February 2024 | September 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18578530 | IMIDAZO[1,2-B][1,2,4]TRIAZOL DERIVATIVES FOR USE IN THERAPY | January 2024 | March 2026 | Allow | 26 | 0 | 0 | No | No |
| 18408663 | METHODS OF TREATING BACTERIAL INFECTIONS | January 2024 | June 2025 | Allow | 17 | 1 | 1 | No | No |
| 18495004 | MK2 INHIBITORS AND USES THEREOF | October 2023 | February 2026 | Allow | 28 | 1 | 0 | No | No |
| 18285788 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | October 2023 | November 2025 | Allow | 25 | 0 | 0 | No | No |
| 18275119 | INHIBITORS OF PROTEIN KINASE A | July 2023 | November 2025 | Allow | 28 | 0 | 0 | No | No |
| 18273360 | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | July 2023 | November 2025 | Allow | 28 | 0 | 0 | No | No |
| 18261778 | HECT E3 UBIQUITIN LIAGASE INHIBITORS AND USES THEREOF | July 2023 | October 2025 | Allow | 27 | 0 | 0 | No | No |
| 18038364 | SPIROCYCLIC-SUBSTITUTED 6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT | May 2023 | January 2026 | Allow | 32 | 1 | 0 | No | No |
| 18252423 | CRYSTAL FORMS OF 5-FLUORO-1-(4-FLUORO-3-(4-(PYRIMIDIN-2-YL)PIPERAZINE-1-CARBONYL)BENZYL)QUINAZOLINE-2,4(1H,3H)-DIONE AND PREPARATION THEREOF | May 2023 | September 2025 | Allow | 28 | 0 | 0 | No | No |
| 18245999 | A PHARMACEUTICAL SALT OF AN ARYLPYRROLE DERIVATIVE | March 2023 | December 2025 | Allow | 33 | 1 | 0 | No | No |
| 18024722 | PROCESS FOR PREPARING A TETRAZOLE-SUBSTITUTED ANTHRANILIC ACID DIAMIDE DERIVATIVE | March 2023 | December 2025 | Allow | 34 | 0 | 1 | No | No |
| 18175630 | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH ELEVATED ARGININE VASOPRESSIN LEVELS | February 2023 | November 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18175252 | TREATMENT OF SCHIZOPHRENIA USING BETA-CARYOPHYLLENE AND CB2 RECEPTOR AGONISTS | February 2023 | January 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18172875 | TRIENTINE TETRAHYDROCHLORIDE AND A METHOD OF PREPARATION AND A PHARMACEUTICAL COMPOSITION THEREOF | February 2023 | February 2025 | Allow | 23 | 3 | 0 | Yes | No |
| 18101611 | METHODS OF TREATING BACTERIAL INFECTIONS | January 2023 | September 2025 | Abandon | 31 | 4 | 1 | Yes | No |
| 18016164 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | January 2023 | November 2025 | Allow | 34 | 1 | 0 | No | No |
| 18015997 | CRYSTAL OF PYRIMIDINE COMPOUND | January 2023 | August 2025 | Allow | 31 | 1 | 0 | No | No |
| 18151265 | COMPOSITION COMPRISING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT, FOR PREVENTING OR AMELIORATING FATIGUE, CACHEXIA, PAIN, COGNITIVE DECLINE AND HEMATOPOIETIC STEM CELL REDUCTION WHICH ARE SIDE EFFECTS RELATED TO ANTICANCER DRUG TREATMENT | January 2023 | March 2025 | Allow | 27 | 3 | 0 | No | No |
| 18069030 | SMALL MOLECULE INHIBITORS OF CALCIUM CHANNEL ACTIVITY AND USES THEREOF | December 2022 | November 2025 | Allow | 35 | 5 | 0 | No | No |
| 18002187 | NOVEL COMPOUNDS | December 2022 | December 2025 | Allow | 36 | 1 | 0 | No | No |
| 18079904 | ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE | December 2022 | September 2024 | Allow | 21 | 2 | 0 | No | No |
| 18061127 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | December 2022 | April 2024 | Allow | 17 | 1 | 1 | No | No |
| 18007840 | PYRIDINYL MORPHOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | December 2022 | June 2025 | Allow | 31 | 0 | 0 | No | No |
| 17928719 | TREATMENT FOR THE INFLAMMATORY BOWEL DISEASE | November 2022 | February 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17924863 | SMALL MOLECULE INHIBITORS OF CAV3.2 ACTIVITY AND USES THEREOF | November 2022 | July 2025 | Allow | 32 | 3 | 0 | No | No |
| 17984405 | PHARMACEUTICAL COMPOSITIONS OF SPIRONOLACTONE FOR DEEP DERMAL DRUG DELIVERY | November 2022 | July 2025 | Allow | 32 | 4 | 0 | Yes | No |
| 17997288 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | October 2022 | July 2025 | Allow | 33 | 0 | 1 | No | No |
| 18049547 | PIPERIDINYLPYRAZINE-CARBOXAMIDE COMPOUNDS FOR TREATING AND PREVENTING CANCER AND FOR DEGRADING BTK | October 2022 | March 2025 | Allow | 29 | 4 | 0 | No | No |
| 17921043 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | October 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17919490 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | October 2022 | August 2025 | Allow | 34 | 1 | 0 | No | No |
| 17966717 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | October 2022 | September 2025 | Abandon | 35 | 2 | 1 | Yes | No |
| 17917571 | COMPOSITION FOR CANCER PREVENTION OR TREATMENT, CONTAINING, AS ACTIVE INGREDIENT, SALVIANOLIC ACID B OR TANSHINONE I | October 2022 | November 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17995564 | METHODS FOR SYNTHESIS OF CHK1 INHIBITORS | October 2022 | December 2025 | Allow | 38 | 1 | 1 | No | No |
| 17954047 | COMPOUNDS AS GLP-1R AGONISTS | September 2022 | December 2024 | Abandon | 26 | 2 | 1 | No | No |
| 17913936 | USE OF AGENTS FOR TREATMENT OF RESPIRATORY CONDITIONS | September 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17912842 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | September 2022 | April 2025 | Abandon | 31 | 0 | 0 | No | No |
| 17909292 | COMBINATION OF AN LSD-1 INHIBITOR AND NIVOLUMAB FOR USE IN TREATING SCLC OR SQNSCLC | September 2022 | August 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17905072 | COMPOUNDS AS CDK2/4/6 INHIBITORS | August 2022 | November 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17820522 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER | August 2022 | November 2025 | Allow | 39 | 1 | 1 | No | No |
| 17929007 | PHYSICS-DRIVEN DISCOVERY OF NOVEL SMALL THERAPEUTIC COMPOUNDS FOR USE AS A BCL-2 INHIBITOR | August 2022 | April 2025 | Allow | 32 | 1 | 0 | No | No |
| 17798605 | USE OF PYRIDO[1,2-A]PYRIMIDINONE COMPOUND IN TREATING LYMPHOMA | August 2022 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17929003 | PHYSICS-DRIVEN DISCOVERY OF NOVEL SMALL THERAPEUTIC COMPOUNDS FOR USE AS A BCL-2 INHIBITOR | August 2022 | June 2025 | Allow | 34 | 1 | 0 | No | No |
| 17875532 | SALTS AND SOLID STATE FORMS OF PLINABULIN | July 2022 | July 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17792792 | IRAK4 INHIBITOR CRYSTAL AND PREPARATION METHOD THEREFOR | July 2022 | April 2025 | Allow | 33 | 1 | 0 | No | No |
| 17810620 | TREATMENT OF ANEURYSMS | July 2022 | March 2025 | Allow | 32 | 3 | 1 | No | No |
| 17848554 | COMPOSITION FOR TREATING OR PREVENTING CLIMACTERIC DISORDERS | June 2022 | October 2024 | Abandon | 28 | 2 | 0 | No | No |
| 17757699 | COMPOSITION FOR TREATING SYNUCLEINOPATHIES | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17786491 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17784401 | IRAK DEGRADERS AND USES THEREOF | June 2022 | October 2025 | Allow | 40 | 1 | 0 | No | No |
| 17782478 | Solid Forms of 2-((4-((S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt | June 2022 | November 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17756888 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | June 2022 | July 2025 | Allow | 38 | 1 | 0 | No | No |
| 17756391 | THIOPHENE DERIVATIVES | May 2022 | December 2025 | Allow | 42 | 1 | 1 | No | No |
| 17778582 | MACROCYLIC SULFONYL DERIVATIVES MCL-1 INHIBITORS | May 2022 | October 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17664026 | PYRROLOTRIAZINE COMPOUNDS ACTING AS MNK INHIBITOR | May 2022 | July 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17739506 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | May 2022 | October 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17775458 | SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | May 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17773098 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | April 2022 | March 2025 | Allow | 35 | 0 | 0 | No | No |
| 17770469 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | April 2022 | September 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17769787 | METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17768429 | Phospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer Therapy | April 2022 | July 2025 | Allow | 39 | 1 | 0 | No | No |
| 17768174 | [1,4]OXAZEPINO[2,3-C]QUINOLINONE DERIVATIVES AS BCL6 INHIBITORS | April 2022 | August 2025 | Allow | 40 | 1 | 0 | No | No |
| 17693067 | METHODS OF TREATING BINGE EATING DISORDER | March 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17641485 | CLASS OF FUNCTIONAL MOLECULES TARGETING PROTEOLYSIS PATHWAYS, PREPARATION AND APPLICATION THEREOF | March 2022 | February 2025 | Allow | 36 | 0 | 0 | No | No |
| 17639724 | PHARMACEUTICAL FORMULATIONS COMPRISING DICLOFENAC | March 2022 | October 2025 | Allow | 43 | 1 | 1 | No | No |
| 17636426 | PROSTATITIS TREATMENT | February 2022 | July 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17667083 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | February 2022 | March 2026 | Allow | 49 | 3 | 1 | No | No |
| 17631765 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF | January 2022 | April 2025 | Allow | 38 | 0 | 1 | No | No |
| 17626075 | ADENOSINE A2A RECEPTOR ANTAGONISTS | January 2022 | July 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17621457 | NOVEL COMPOUNDS | December 2021 | December 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17619733 | COMPOSITION FOR THE TREATMENT OF MUSCLE WASTING | December 2021 | November 2025 | Allow | 47 | 2 | 1 | No | No |
| 17614815 | METHODS OF TREATING FIBROSIS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | November 2021 | October 2025 | Allow | 47 | 2 | 1 | No | No |
| 17614053 | MICROBIOCIDAL DERIVATIVES | November 2021 | September 2025 | Allow | 46 | 2 | 1 | No | No |
| 17595745 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES COMPRISING NAPHTHOQUINONE DERIVATIVE | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17531216 | STABLE ANTIEMETIC EMULSIONS | November 2021 | September 2024 | Allow | 34 | 2 | 0 | No | No |
| 17595470 | SUSTAINED RELEASE LOCAL ANESTHETIC HYDROGEL COMPOSITION | November 2021 | July 2025 | Allow | 43 | 1 | 1 | No | No |
| 17611974 | Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent Against Gram-Negative Bacteria | November 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17612014 | TRANSITIONING PATIENTS TREATED FOR PULMONARY ARTERIAL HYPERTENSION TO SELEXIPAG | November 2021 | June 2025 | Allow | 43 | 2 | 0 | No | No |
| 17611448 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | November 2021 | July 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17611544 | TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS | November 2021 | April 2025 | Allow | 41 | 1 | 0 | No | No |
| 17611051 | COMPOSITION COMPRISING GOSSYPETIN FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE | November 2021 | July 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17610570 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | November 2021 | November 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17610617 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | November 2021 | November 2025 | Allow | 48 | 2 | 1 | No | No |
| 17610276 | METHOD AND COMPOSITION FOR TREATMENT OF SKIN DISEASES ASSOCIATED WITH ACCELERATED CORNEODESMOSOMES DEGRADATION OR WEAKER CELL-CELL ADHESION | November 2021 | October 2025 | Allow | 47 | 1 | 1 | No | No |
| 17521195 | BRM Targeting Compounds And Associated Methods Of Use | November 2021 | June 2025 | Allow | 43 | 2 | 1 | No | No |
| 17609034 | A PHARMACEUTICAL INTERMEDIATE | November 2021 | September 2024 | Allow | 35 | 0 | 0 | No | No |
| 17607449 | SOLID FORM OF DIAMINOPYRIMIDINE COMPOUND OR HYDRATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | October 2021 | December 2024 | Allow | 38 | 1 | 0 | No | No |
| 17607595 | INHIBITING USP36 | October 2021 | December 2025 | Allow | 49 | 1 | 1 | No | No |
| 17606294 | IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE | October 2021 | April 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17605402 | USE OF COMPOUND IN PREPARATION OF DRUG FOR TREATING ATHEROSCLEROSIS | October 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17605206 | 8-SUBSTITUTED ARYL VINYL XANTHINE DERIVATIVES AND USES THEREOF | October 2021 | January 2026 | Abandon | 50 | 2 | 1 | No | No |
| 17602408 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | October 2021 | July 2024 | Allow | 34 | 0 | 0 | No | No |
| 17602133 | CHRYSOPHAENTIN ANALOGS AND USE THEREOF | October 2021 | April 2025 | Allow | 42 | 1 | 1 | No | No |
| 17602139 | ANTI-FUNGAL AGENT | October 2021 | July 2024 | Allow | 33 | 2 | 1 | No | No |
| 17594128 | COMBINED USE OF A-NOR-5alpha ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG | October 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SEITZ, ANTHONY JOSEPH.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SEITZ, ANTHONY JOSEPH works in Art Unit 1629 and has examined 130 patent applications in our dataset. With an allowance rate of 64.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 43 months.
Examiner SEITZ, ANTHONY JOSEPH's allowance rate of 64.6% places them in the 25% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by SEITZ, ANTHONY JOSEPH receive 1.52 office actions before reaching final disposition. This places the examiner in the 27% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SEITZ, ANTHONY JOSEPH is 43 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +33.9% benefit to allowance rate for applications examined by SEITZ, ANTHONY JOSEPH. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 36.0% of applications are subsequently allowed. This success rate is in the 81% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 77.8% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.8% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.